Impaired Pancreatic β-Cell Function in Critically Ill Children

Area of Science:

• Pediatric Endocrinology
• Critical Care Medicine
• Metabolic Disorders

Background:

• Critical illness hyperglycemia (CIH) is a frequent complication in pediatric intensive care units (PICUs).
• Key mechanisms include increased glucose production, insulin resistance (IR), and pancreatic beta-cell dysfunction.
• Understanding beta-cell function is crucial for managing CIH and predicting outcomes.

Purpose of the Study:

• To investigate pancreatic beta-cell function in pediatric patients experiencing critical illness.
• To explore the relationship between beta-cell function and clinical/laboratory variables.
• To determine the association between beta-cell function and intensive care unit (ICU) mortality.

Main Methods:

• Prospective recruitment of 91 pediatric patients in the ICU.
• Assessment of pancreatic beta-cell function using the homeostasis model assessment (HOMA)-beta.
• Analysis of clinical data, laboratory markers (e.g., C-reactive protein), and ICU mortality.

Main Results:

• Patients with HOMA-beta <40.0% exhibited higher PRISM III scores, elevated CRP, lower IR, and longer hospital stays.
• Insulin resistance varied with beta-cell function: highest at 40-80% and intermediate at >80%.
• ICU survivors demonstrated significantly better beta-cell function compared to non-survivors.

Conclusions:

• Pancreatic beta-cell dysfunction is prevalent in critically ill children.
• Impaired beta-cell function (HOMA-beta <80.0%) and higher PRISM III scores are significant predictors of ICU mortality.
• Beta-cell dysfunction plays a critical role in the morbidity and mortality of pediatric ICU patients.